Rationally designed treatment for solid tumors with MAPK pathway activation: A phase I study of paclitaxel and bortezomib using an adaptive dose-finding approach

Molecular Cancer Therapeutics

Volumn 10, Issue 8, 2011, Pages 1509-1519

  Mehnert, Janice M ^a,d   Tan, Antoinette R ^a,d   Moss, Rebecca ^a,d   Poplin, Elizabeth ^a,d   Stein, Mark N ^a,d   Sovak, Mika ^a,d   Levinson, Kelly ^d   Lin, Hongxia ^d   Kane, Michael ^a   Gounder, Murugesan ^a,d   Lin, Yong ^b,d   Shih, Weichung Joe ^b,d   White, Eileen ^c,d   Rubin, Eric H ^a,d   Karantza, Vassiliki ^a,d  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^c RUTGERS UNIVERSITY   (United States)

^d RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; RAF PROTEIN; RAS PROTEIN;

ADULT; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; CHILL; CLINICAL ARTICLE; COLON CANCER; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG TOLERABILITY; DYSPNEA; ENZYME ACTIVATION; FATIGUE; FEMALE; FEVER; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; LIMB PAIN; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OVARY CANCER; PANCREAS TUMOR; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SENSORY NEUROPATHY; SOLID TUMOR; TIME TO MAXIMUM PLASMA CONCENTRATION; TINNITUS; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MAXIMUM TOLERATED DOSE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; PACLITAXEL; PYRAZINES; TREATMENT OUTCOME;

EID: 80051599199     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-10-0944     Document Type: Article

References (40)

1. Einzig AI, Neuberg D, Wiernik PH, Grochow LB, Ramirez G, O'Dwyer PJ, et al. Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: an eastern cooperative oncology group trial (PA286). Am J Ther 1996;3:750-4. (Pubitemid 27120326)
2. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene 2003;22:8590-607. (Pubitemid 38028528)
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70. (Pubitemid 30046295)
4. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010;37:299-310.
5. Tan TT, Degenhardt K, Nelson DA, Beaudoin B, Nieves-Neira W, Bouillet P, et al. Key roles of BIM-driven apoptosis in epithelial tumors and rational chemotherapy. Cancer Cell 2005;7:227-38. (Pubitemid 40568682)
6. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47. (Pubitemid 39626217)
7. Burger M, Denzinger S, Hammerschmied C, Tannapfel A, Maderstorfer A, Wieland WF, et al. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations. Eur Urol 2006;50:1102-9.
8. Weber MJ, Gioeli D. Ras signaling in prostate cancer progression. J Cell Biochem 2004;91:13-25.
9. Bradbury J. Genotypic guidance for chemotherapy choices. Drug Discov Today 2005;10:608. (Pubitemid 40704766)
10. Finnberg N, El-Deiry WS. Paclitaxel and velcade: the rationale for a combo. Cancer Biol Ther 2005;4:631-4. (Pubitemid 41351202)
11. Li R, Moudgil T, Ross HJ, Hu HM. Apoptosis of non-small cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim. Cell Death Differ 2005;12:292-303. (Pubitemid 40360952)
12. Sunters A, Fernandez de Mattos S, Stahl M, Brosens JJ, Zoumpoulidou G, Saunders CA, et al. FoxO3a transcriptional regulation of Bim controls apoptosis in paclitaxel-treated breast cancer cell lines. J Biol Chem 2003;278:49795-805. (Pubitemid 37548813)
13. Moore PS, Barbi S, Donadelli M, Costanzo C, Bassi C, Palmieri M, et al. Gene expression profiling after treatment with the histone deacetylase inhibitor trichostatin A reveals altered expression of both pro- and antiapoptotic genes in pancreatic adenocarcinoma cells. Biochim Biophys Acta 2004;1693:167-76.
14. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, et al. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004;3:895-902. (Pubitemid 39199584)
15. Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, et al. A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2010;66:151-8.
16. Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, et al. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemother Pharmacol 2007;59:207-15. (Pubitemid 44885150)
17. Croghan GA, Suman VJ, Maples WJ, Albertini M, Linette G, Flaherty L, et al. A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer 2010;116:3463-8.
18. Cresta S, Sessa C, Catapano CV, Gallerani E, Passalacqua D, Rinaldi A, et al. Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. Eur J Cancer 2008;44:1829-34.
19. Williams SA, Papandreou C, McConkey D. Preclinical effects of proteasome inhibitor PS-341 in combination chemotherapy for prostate cancer. Proc Am Soc Clin Oncol 2001;20:169b.
20. Goodman SN, Zahurak ML, Piantadosi S. Some practical improvements in the continual reassessment method for phase I studies. Stat Med 1995;14:1149-61.
21. Piantadosi S, Fisher JD, Grossman S. Practical implementation of a modified continual reassessment method for dose-finding trials. Cancer Chemother Pharmacol 1998;41:429-36. (Pubitemid 28140705)
22. Faries D. Practical modifications of the continual reassessment method for phase I cancer clinical trials. J Biopharm Stat 1994;4:147-64. (Pubitemid 24248939)
23. O'Quigley J, Shen LZ. Continual reassessment method: a likelihood approach. Biometrics 1996;52:673-84. (Pubitemid 26187071)
24. Schwartz R, Davidson T. Pharmacology, pharmacokinetics, and practical applications of bortezomib. Oncology 2004;18:14-21.
25. Kane RC, Farrell AT, Sridhara R, Pazdur R. United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin Cancer Res 2006;12:2955-60. (Pubitemid 43837337)
26. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
27. Toppmeyer DL, Gounder M, Much J, Musanti R, Vyas V, Medina M, et al. A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy. Med Sci Monit 2003;9:PI99-104.
28. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, Wickenden JA, Balmanno K, Gilley R, et al. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J 2007;26:2856-67. (Pubitemid 46975775)
29. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, et al. Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002;8:1168-71. (Pubitemid 35177371)
30. Naoki K, Kunikane H, Fujii T, Tsujimura S, Hida N, Okamoto H, et al. Dose-escalating and pharmacokinetic study of a weekly combination of paclitaxel and carboplatin for inoperable non-small cell lung cancer: JCOG 9910-DI. Jpn J Clin Oncol 2009;39:569-75.
31. Chen Y, Pandya KJ, Feins R, Johnstone DW, Watson T, Smudzin T, et al. Toxicity profile and pharmacokinetic study of a phase I low-dose schedule-dependent radiosensitizing paclitaxel chemoradiation regimen for inoperable non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2008;71:407-13.
32. Leiser AL, Maluf FC, Chi DS, Sabbatini P, Hensley ML, Schwartz L, et al. A phase I study evaluating the safety and pharmacokinetics of weekly paclitaxel and carboplatin in relapsed ovarian cancer. Int J Gynecol Cancer 2007;17:379-86. (Pubitemid 46426769)
33. Schneider B, Fukunaga A, Murry D, Yoder C, Fife K, Foster A, et al. A phase I, pharmacokinetic and pharmacodynamic dose escalation trial of weekly paclitaxel with interferon-alpha2b in patients with solid tumors. Cancer Chemother Pharmacol 2007;59:261-8. (Pubitemid 44885155)
34. Gadducci A, Katsaros D, Zola P, Scambia G, Ballardini M, Pasquini E, et al. Weekly low-dose paclitaxel as maintenance treatment in patients with advanced ovarian cancer who had microscopic residual disease at second-look surgery after 6 cycles of paclitaxel/platinum-based chemotherapy: results of an open noncomparative phase 2 multicenter Italian study (After-6 Protocol 2). Int J Gynecol Cancer 2009;19:615-9.
35. Hess V, Verrill MW, Bomphray CC, Vaughan MM, Allen M, Gore ME. Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma. Ann Oncol 2003;14:638-42. (Pubitemid 41295095)
36. Inada S, Tomidokoro T, Fukunari H, Sato T, Hatano T, Nishimura A, et al. Phase I/II trial of combination therapy with S-1 and weekly paclitaxel in patients with unresectable or recurrent gastric cancer. Cancer Chemother Pharmacol 2009;63:267-73.
37. Wu CH, Yang CH, Lee JN, Hsu SC, Tsai EM. Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. Int J Gynecol Cancer 2001;11:295-9. (Pubitemid 32751398)
38. Uhlmann C, Ballabeni P, Rijken N, Brauchli P, Mingrone W, Rauch D, et al. Capecitabine with weekly paclitaxel for advanced breast cancer: a phase I dose-finding trial. Oncology 2004;67:117-22. (Pubitemid 39482679)
39. Rushing DA. Phase I/II study of weekly irinotecan and paclitaxel in patients with SCLC. Oncology 2000;14:63-6.
40. Edelman MJ, Burrows W, Krasna MJ, Bedor M, Smith R, Suntharalingam M. Phase I trial of carboplatin/paclitaxel/bortezomib and concurrent radiotherapy followed by surgical resection in Stage III non-small cell lung cancer. Lung Cancer 2010;68:84-8.